Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians  by Arai, Yasumichi et al.
EBioMedicine 2 (2015) 1549–1558
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch ArticleInﬂammation, But Not Telomere Length, Predicts Successful Ageing at
Extreme Old Age: A Longitudinal Study of Semi-supercentenariansYasumichi Arai a,1, Carmen M. Martin-Ruiz b,1, Michiyo Takayama c, Yukiko Abe a, Toru Takebayashi d,
Shigeo Koyasu f,g, Makoto Suematsu a,e, Nobuyoshi Hirose a,⁎,2, Thomas von Zglinicki b,⁎⁎,2
a Centre for Supercentenarian Research, Keio University School of Medicine, Tokyo, Japan
b Newcastle University Institute for Ageing, Campus for Ageing and Vitality, Newcastle University, UK
c Centre for Preventive Medicine, Keio University School of Medicine, Tokyo, Japan
d Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan
e Department of Biochemistry, Keio University School of Medicine, and JST, ERATO, Suematsu Gas Biology Project, Tokyo, Japan
f Laboratory for Immune Cell Systems, RIKEN Centre for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, Japan
g Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, JapanAbbreviations: IL-6, interleukin 6; TNF-alpha, tumour ne
CMV, cytomegalovirus; LTL, leukocyte telomere length; TOO
Total Health; TCS, Tokyo Centenarians Study; JSS, Japanese
CRP, C-reactive protein; NK cells, natural killer cells; CD,
aspartate aminotransferase or aspartate transaminase; A
alanine transaminase; GGTP, gamma-glutamyl-transpepti
SD, standard deviation; ANOVA, analysis of variance; ELISA,
assay; PCR, polymerase chain reaction; MMSE, Mini-Mental
vascular disease; eGFR, estimated glomerular ﬁltration rate
⁎ Correspondence to: N. Hirose, Centre for Supercenten
School of Medicine, 35, Shinanomachi, Shinjuku-ku, Toky
⁎⁎ Correspondence to: T. von Zglinicki, Newcastle U
Campus for Ageing and Vitality, Newcastle University, New
E-mail addresses: hirosen@keio.jp (N. Hirose), t.vonzglinick
1 Contributed equally to this manuscript.
2 Shared senior authors.
http://dx.doi.org/10.1016/j.ebiom.2015.07.029
2352-3964/Crown Copyright © 2015 Published by Elseviea b s t r a c ta r t i c l e i n f oArticle history:
Received 3 June 2015
Received in revised form 20 July 2015
Accepted 22 July 2015





TelomereTo determine the most important drivers of successful ageing at extreme old age, we combined community-
based prospective cohorts: Tokyo Oldest Old Survey on Total Health (TOOTH), Tokyo Centenarians Study (TCS)
and Japanese Semi-Supercentenarians Study (JSS) comprising 1554 individuals including 684 centenarians and
(semi-)supercentenarians, 167 pairs of centenarian offspring and spouses, and 536 community-living very old
(85 to 99 years). We combined z scores from multiple biomarkers to describe haematopoiesis, inﬂammation,
lipid and glucosemetabolism, liver function, renal function, and cellular senescence domains. In Cox proportional
hazard models, inﬂammation predicted all-cause mortality with hazard ratios (95% CI) 1.89 (1.21 to 2.95)
and 1.36 (1.05 to 1.78) in the very old and (semi-)supercentenarians, respectively. In linear forward stepwise
models, inﬂammation predicted capability (10.8% variance explained) and cognition (8.6% variance explained)
in (semi-)supercentenarians better than chronologic age or gender. The inﬂammation score was also lower
in centenarian offspring compared to age-matched controls with Δ (95% CI) =−0.795 (−1.436 to−0.154).
Centenarians and their offspring were able to maintain long telomeres, but telomere length was not a predictor
of successful ageing in centenarians and semi-supercentenarians.We conclude that inﬂammation is an important
malleable driver of ageing up to extreme old age in humans.
Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY license
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With continuously increasing life expectancy, the impact of chronic
diseases and dependencies, for which no speciﬁc cures are available,
also increases. This leads to an enormous burden to individuals and
societies alike, which threatens to overwhelm conventional curative
and care models in medicine. Unfortunately healthy life expectancy,
the number of years spent free of disabilities, has grown slower than
life expectancy in a number of countries. Within the European Union,
for instance, life expectancy at age 50 has grown by 1.2 years between
2005 and 2010, but healthy life expectancy has only grown slightly
(0.5 years in men, 0.4 years in women) in the same time frame
(Fouweather et al., 2015). Moreover, this has been accompanied by
increasing inequalities between EU countries in healthy life span, driven
preferentially by material deprivation and long-term unemployment
rates (Fouweather et al., 2015).
Centenarians and (semi-)supercentenarians are regarded as model
cases for ‘successful ageing’. Centenarians retain independence andnder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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population, together with postponed mortality (Andersen et al., 2012;
Arai et al., 2014; Pavlidis et al., 2012). Understanding the factors deter-
mining extreme longevity and compression of morbidity might help to
achieve extended healthy life span for the wider population and to close
the gap between the fastest and the slowest ageing population groups.
Moreover, the proportion of centenarians and (semi-)supercentenarians
in the population is growing fast making understanding of the relative
importance of the factors that determine successful ageing at extreme
age a relevant objective in its own right.
Such understanding cannot simply be extrapolated from results
obtained in younger populations because the power of biomarkers to
predict the impact of various pathophysiological mechanisms on suc-
cessful ageing is frequently dependent on age itself (Martin-Ruiz and
von Zglinicki, 2014). For late nonagenarians and centenarians, some rel-
atively small studies have shown improved or at least well maintained
levels of certain biomarkers including immunosenescence markers
(Strindhall et al., 2007) but data on telomere length, a prominent marker of
cell senescence, were contradictory in this age group (Atzmon et al., 2010;
Kimura et al., 2007; Tedone et al., 2014). In contrast, chronic inﬂammation
is a strong negative predictor of successful ageing in younger cohorts (Jenny
et al., 2012) and a cause of accelerated ageing in mice (Jurk et al., 2014) but
appears to lose predictive power in centenarians (Gangemi et al., 2005). On
this basis, it has been suggested that inﬂammation might change its role to-
wards a pro-longevity factor at extreme old age (Salvioli et al., 2013).
Little is known about changes in biomarkers as centenarians progress
towards even higher age. To our knowledge, there is only one small study
reporting changes in telomere length between Italian centenarians and
semi-supercentenarians (Tedone et al., 2014), which included only 29
semi-supercentenarians. So far, nothing is known about the relative
power of biomarkers delineating different pathophysiological domains to
predict successful ageing in centenarians and (semi-)supercentenarians.
Through a nation-wide recruitment effort, we established unique
cohorts of centenarians and (semi-)supercentenarians with a maxi-
mum of 10-year mortality follow-up to identify genetic and biological
pathways to healthy ageing and longevity using both cross-sectional
and longitudinal approaches (Arai et al., 2014). These unique cohorts
are supported by cohorts representing the oldest non-centenarians
(Arai et al., 2010) as well as centenarian offspring and their spouses.
We obtained quantitative measures of successful ageing, namely
capability (Barthel index), multi-morbidity (disease count), cognitive
function (MMSE score), and mortality (survival time). In addition, we
generated biomarker data covering multiple relevant domains, which
were each characteristic of a pathophysiological process with the poten-
tial to drive ageing. These domains are haematopoiesis/anaemia, inﬂam-
mation, lipid and glucose metabolism, liver function, renal function, and
cell-/immuno-senescence. This allowed us to address two important
questions: i) which biological processes (measured by biomarker
domain) are the most important predictors of successful ageing at
extreme age? and ii) are the same processes active in both centenarians/
(semi-)supercentenarians and their offspring?
Together, our results suggest that suppressionof inﬂammation is themost
important driver of successful longevity that increases in importance with
advancing age and is amenable to pharmacological intervention.2. Methods
2.1. Study Population
The analytical cohort of this study comprised 1554 individuals includ-
ing: 684 centenarians (100–104 years old) and (semi-)supercentenarians
(105 years or older), 167 pairs of offspring and unrelated family (spouse
of offspring) of centenarians, and 536 community-living very old (85 to
99 years), covering a wide range of chronological ages from around 50
up to 115 years. Sample size was primarily determined by availability.Written informed consent to participate was obtained either from
the participants or proxy when individuals lacked the capacity to con-
sent. The studywas approved by the Ethical Committee of the Keio Uni-
versity School of Medicine.
Samples of centenarians were derived from two prospective
cohorts, the Tokyo Centenarians Study (TCS) and the Japanese Semi-
supercentenarians Study (JSS). Details of cohort recruitment were
described previously (Arai et al., 2010; Gondo et al., 2006; Takayama
et al., 2007). The TCS took place from July 2000 to May 2002, and 304
centenarians living in the Tokyo metropolitan area (65 men, 239
women) were recruited based on the basic resident registry. Amongst
them, 255 centenarians (58 men, 197 women, median age 100.7, IQR;
100.2–102.1 years) with enough DNA sample for telomere measure-
ments were included in this analysis. The JSS is a nationwide longitudi-
nal survey that involves mainly (semi-)supercentenarians, individuals
aged 105 years or older. Between September 2002 and November
2011, a total of 429 centenarians (51 men, 378 women, median age
106.7 years, IQR; 105.6–107.6 years, 90.2% were older than 105 years)
were enrolled in the JSS. As the main aim of JSS is to identify
longevity-assurance genes, DNA samples to perform telomere length
measurements were available from all JSS participants. On the basis of
the Japanese cohort life tables, 122 and 617 men and women, respec-
tively, per 100,000 births reached 100 years of age in 2000, while
there were 12 and 90 per 100,000 births to reach an age of 105 in
2005, and the ratios to reach 110 years in 2010 were 0.3 and 6.6 per
100,000 births. Indeed only 13.9% and 0.9% of those who reached
100 years old then survived to 105 and 110 years old, respectively.
Therefore,we examined associations between biomarkers and outcome
indicators separately according to age at recruitment. During the
recruitment process, we also recruited a ﬁrst-degree offspring of cente-
narians (n = 167) and their spouses (n = 167) as unrelated family. In
the Japanese tradition, elder sons are the most likely carers of their
parents, thus 75.4% of offspring were male and exactly the same rate
were female in the unrelated family cohort. Samples of the very old
were derived from a community-based prospective cohort of the
TokyoOldest Old Survey on TotalHealth (TOOTH). The design, recruitment,
and entire procedure of the TOOTH were previously described (Arai et al.,
2014). Brieﬂy, between March 2008 and November 2009, we recruited a
randomly selected sample of 984 inhabitants of Tokyo aged 85 years or
older for face-to-face interviews at the participants' residences, of which
542 (236 men, 306 women; mean ± SD age, 87.8 ± 2.2 years; range,
85–102 years) participated in extended medical examination. Amongst
them, 2 individuals aged 100 years or older and 4 lacking a DNA sample
were excluded, leaving 536 to be enrolled in this analysis.
Participants were assessed and examined by trained geriatricians
(N.H., Y.A., and M.T.) according to protocols described (Arai et al.,
2014, 2010; Gondo et al., 2006; Takayama et al., 2007).
2.2. Outcomes
The outcomes of interest were cognitive status, capability, multi-
morbidity and death. In the extreme old, these scalable variables are
more informative than dichotic variables (e.g., frailty, diagnosed
dementia). We established death from any cause (all centenarians and
TOOTH participants) and death from cardiovascular disease (CVD),
cancer, and pneumonia (TOOTH participants only). For both the TCS
and JSS cohorts, information onmortality was ascertained by telephone
contact or mail survey conducted every 12 months until 30 September
2012 with a 249,548 person-day (median period, 752 days; range,
3–4143 days) follow-up for the TCS and a 248,846 person-day (median
period, 503 days; range, 1–2561 days) follow-up for the JSS. During
follow-up, there were 249 (97.6%) deaths, one participant (0.4%) was
alive, and 5 (2.0%) were lost to follow-up in the TCS cohort. In JSS
there were 375 (87.4%) deaths, 45 participants (10.5%) were alive, and
9 (2.1%) were lost to follow-up. Most of the (semi-)supercentenarians
who remained in the cohort were those who were enrolled in recent
1551Y. Arai et al. / EBioMedicine 2 (2015) 1549–1558years. For the TOOTH cohort (85–99 years at enrollment), participants
were followed up for all-cause and cause-speciﬁcmortality by telephone
contact or mail survey conducted every 12months (Iinuma et al., 2015).
At 3 years, those who remained in the cohort were examined according
to the sameprotocol as in the baseline survey (ﬁrst follow-up survey). There-
after, themortality surveywas extended and 4 year-follow-upwas complet-
ed by the end of November 2013. Total follow-up timewas 669,390 person-
days (median period, 1460 days; range, 27–1460 days). There were 123
(22.9%) deaths, amongst them 32 related to cancers, 36 to CVD, 25 to pneu-
monia, 17 to advanced age, 4 to severe dementia, and 9 by unknown causes.
Additional outcomes of interest were cognitive function which was
evaluated according to the Mini-Mental State Examination (MMSE),
capability (assessed using the Barthel Index) and multi-morbidity.
Information regarding past medical history was obtained from partici-
pants or care giver/proxy when participants lacked capacity, and from
available documentations including discharge summary and medication
list. The classiﬁcation ofmedical conditionswas based on the Internation-
al Classiﬁcation of Diseases, 10th Revision. A total of 8 chronic conditions,
i.e. hypertension [I10], coronary heart disease [I20–I25], stroke [I60–I69],
Diabetes mellitus [E11], hyperlipidaemia [E78], fragility fracture [M80],
cancer (excluding skin cancer, [C00–C41, C45–67]) and renal disease
[N00–N19], were incorporated into the multimorbidity count. Chronic
kidney disease was not included because its diagnosis in the oldest old
has not been validated.
2.3. Biomarkers
Non-fasting blood samples were obtained at baseline and were
stored at −80 °C until subsequent assay. Total DNA was extracted
from whole blood by using the FlexGene DNA Kit (QIAGEN, Hilden,
Germany) and was stored in FG3 solution at 4 °C (Kojima et al., 2004).
Candidate biomarkers were measured as follows:
Telomere length: A total of 1554 samples from the 3 cohorts includ-
ed in this study were assessed, all by the same lab. DNA concentration
and quality were monitored by agarose gel electrophoresis. No sample
had to be discarded because of DNA degradation. Telomere length was
measured as abundance of telomeric template versus a single copy
gene (36B4) using the following primers: TelA (5′-CGG TTT GTT TGG
GTT TGG GTT TGG GTT TGG GTT TGG GTT-3′); TelB (5′-GGC TTG CCT
TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT-3′); 36B4F (5′-CAG CAA
GTG GGA AGG TGT AAT CC 3′) and 36B4R (5′-CCC ATT CTA TCA TCA
ACG GGT ACA A-3′). Three internal control DNA samples of know telo-
mere length (10.4 kb, 3.9 kb and 2 kb) were run within each plate to
correct for plate–to-plate variation. Measurements were performed in
triplicate. All PCRs were carried out on an Applied Biosystems 7900HT
Fast Real Time PCR system with 384-well plate capacity. The intra-
assay coefﬁcient of variation was 2.7% while the inter-assay coefﬁcient
of variationwas 5.1%. As a further authentication of our telomere length
measurements, we performed 2 revaluation exercises: because of the
extreme longevity of our participants and the likelihood and relevance
of short telomere length values, samples that were in either the 5%
top or 5% bottom of the telomere lengths distribution as well as those
samples that gave no valid data on the ﬁrst run were re-examined.
Throughout, ﬁrst assessments of telomere length were conﬁrmed and
the ﬁnal set of telomere measurements included valid data for 1541
participants (excluding 13 participants for which no valid data could
be generated in two independent experiments). Furthermore, the
impact of batch-to-batch (plate-to-plate) variation was examined
by recombining a set of 192 DNA samples from centenarians and
(semi-)supercentenarians in an independent order onto fresh 96-well
plates and re-measuring them. This validated the absence of signiﬁcant
plate-to-plate bias and speciﬁcally conﬁrmed longer telomeres in
centenarians and (semi-)supercentenarians than expected from the
regression measured at younger ages.
Further biomarkers: Cytomegalovirus (CMV) immunoglobulin G
(IgG) antibody titers were measured by an enzyme immunoassay kit(Denka Seiken Co, Ltd., Tokyo Japan) using Behring ELISA processor III
(Siemens Health Care Diagnostics, Tokyo, Japan). A sample was catego-
rized as seropositive at a relative signal intensity of 2.0 or greater.
Inter-assay CV of CMV IgG titer was 5.66%. Plasma levels of interleukin-
6 (IL-6), and tumour necrosis factor-alpha (TNF-alpha) were measured
in duplicate using commercially available ELISA kits [Quantikine HS
(Human IL-6), R&D Systems, Minneapolis, U.S.A; Quantikine HS
(Human TNF-alpha), R&D Systems, Minneapolis, U.S.A; respectively].
Inter-assay CVs of IL-6 and TNF-alpha were 9.43%, and 8.72%, respective-
ly. Concentrations of C-reactive protein (CRP) were measured using a
standard assay procedure in conjunction with a completely automated
system (SRL Limited, Tokyo, Japan).
Serum creatinine-based eGFR was calculated as below according
to Clinical Practice Guidebook for Diagnosis and Treatment of Chronic
Kidney Disease 2012 (Japanese Society of Nephrology):
eGFR ml=min=1:73m2
  ¼ 194 Cre mg=dlð Þ−1:094
 Age−0:287 0 :739 if femaleð Þ:
To analyse lymphocyte subsetmarkers, whole bloodwas collected in
tubes containing heparin from 17 pairs of offspring and unrelated
family, 8 centenarians and 141 (semi-) supercentenarians, including
27 participants who were enrolled for TCS at an age of 100–104 years
but had the blood sample for lymphocyte phenotyping taken only
after they reached 105years. Accordingly, these 27participantswere in-
cluded in the (semi-)supercentenarian group for analysis of lymphocyte
markers (including the immunosenescence index), but were analysed
as members of the centenarian group with respect to all other markers.
Direct immunoﬂuorescence of lysed whole blood was performed using
ﬂow cytometry (BD FACSCalibur™, BD Bioscience, New Jersey, U.S.A.)
after labelling with ﬂuorochrome conjugated monoclonal antibodies:
anti-CD4-FITC, anti-CD8-PE, anti-CD16-FITC, anti-CD28-FITC, and
CD56-PE (Beckman Coulter, Tokyo, Japan). Twenty thousand light-
scatter (FSC versus SSC) gated events were analysed, and results were
expressed as percentages of total lymphocytes.
2.4. Domain Score Calculation
Biomarkers that showed a strongly skewed distribution (i.e. CMV,
IL-6, TNF-alpha, CRP, aspartate aminotransferase (AST), alanine amino-
transferase (ALT) and gamma-glutamyl-transpeptidase (GGTP)) were
log- converted (natural logarithm).
Data on biomarkers were further organized into domain scores by
linearly combining Z-scores for individual biomarkers as follows:
1. Haematopoiesis: red blood cell count + haematocrit + white blood
cell count.
2. Inﬂammation: CMV titer + IL-6 + TNF-alpha + CRP.
3. Lipid and glucose metabolism: low-density level (LDL) cholesterol +
total cholesterol + glycated haemoglobin (HbA1c).
4. Liver function: AST + ALT + GGTP.
5. Kidney function: estimated glomerular ﬁltration rate (eGFR).
6. Cell senescence: LTL (inverted).
7. Immunosenescence (105+ group only): LTL (inverted) + CD4/CD8
(inverted)+CD16+CD28 (inverted)+CD56 for caseswith available
data.
CMV infection may contribute both to chronic inﬂammation and to
cell senescence (Pawelec et al., 2009). Therefore, alternatively the in-
ﬂammation score was calculated as IL-6 + TNF-alpha + CRP and the
cell senescence score as CMV–LTL. Similarly, there are different opinions
as to whether themonocyte marker CD16 and the NK cell marker CD56
may be regarded as immunosenescence markers (Hayhoe et al., 2010)
and thus the immunosenescence score was alternatively calculated
omitting these two markers. None of the conclusions in this paper was
sensitive to these alternatives (data not shown).
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Baseline characteristics are expressed as means and standard
deviations (SD) or as percentages. Continuous variables with a skewed
distribution are described as medians [interquartile ranges (IQR)], and
log-transformed for statistical analyses. Differences between baseline
characteristics of participants within each age category except cente-
narians' offspring were analysed using the Cochrane–Armitage test for
trend for proportions and analysis of variance for continuous measures.
For longitudinal analysis of age-speciﬁc survival probability, we
plotted Kaplan-Meier mortality curves according to tertiles of each
individual biomarker or each biomarker domain. Because telomere
length, inﬂammatory biomarkers (i.e. interleukin-6, TNF-alpha) and
CMV IgG titers differed substantially among the very old (85–99 years),
centenarians (100–104 years), and (semi)-supercentenarians (105+
years), analyses were performed separately in these groups using age
group-speciﬁc cut-offs of tertiles. A prognostically signiﬁcant result was
deﬁned as log-rank p b 0.05. We used the Cox proportional hazards
model to assess the multivariate-adjusted relative risk for the biomarker
domains. In the multivariate analysis, factors known to be associated
withmortality of the very oldwere included (age, gender, education, his-
tory of cardiovascular disease, hypertension, hyperlipidaemia, diabetes
mellitus, and serum albumin level). Because female participants are
dominant in centenarians, and distribution of smokers, especially current
smokers, were remarkably skewed towards men, we did not include
smoking status in our multiple models. Missing values were excluded
from the respective analyses. For 27 participants of the centenarian
group lymphocyte phenotyping was only performed after they had
turned 105 years. For lymphocyte markers and immunosenescence anal-
yses only, these participants are therefore included in the 105+ group,
andwere dichotomized bymedians because of small numbers of individ-
uals indicated.
We performed automated linear modelling with forward stepwise
model selection using as target variable each of the outcome indicators
Barthel Index, MMSE or multimorbidity (as number of chronic
conditions). Age, gender and all domain scores available in the age
group were included as predictors. Analyses were performed in each
age group separately and over all unrelated age groups combined
(excluding centenarian offspring).
Differences in domain scores between centenarian offspring and
their spouses were assessed by ANOVA for all groups followed by
Tukey post-hoc tests.
All analyses were performed using SPSS ver. 19.0 (SPSS, Chicago, IL,
USA). Results were considered statistically signiﬁcant at a p value of
b0.05 and two-sided tests were applied.
3. Results
3.1. Baseline Characteristics of the Cohorts
Table 1 shows the baseline characteristics of the participants stratiﬁed
by age at recruitment. We found a general increase with age in CMV titer
and inﬂammatory biomarkers and there was a loss of capability and
cognition in centenarians and (semi-)supercentenarians. In contrast,
cardiometabolic risk factors including hypertension, diabetes, and
hyperlipidaemia actually improved at extreme age.
Despite low numbers, supercentenarians tended to display more
‘youthful’ values for many of the biomarkers tested. This trend reversal
occurred even earlier (in the semi-supercentenarians) for two
immunosenescence markers, i.e. the CD4/CD8 ratio, conﬁrming ﬁndings
in a small group of Swedish centenarians (Strindhall et al., 2007), and
telomere length (Table 1). In unrelated individuals, telomeres shortened
with age up to 100 years at rates of 21± 8 (males) and 29±4 (females)
bp/year (Fig. 1). However, after 100 years of age, telomeres increased in
length by 59± 25 (males) and 48± 11 (females) bp/year. Interestingly,
telomeres in centenarian offspring were maintained for more than20 years at a length corresponding to 60 years of age in the general pop-
ulation (Fig. 1). In consequence, telomeres from centenarians, their off-
spring, and, especially, from (semi-)supercentenarians were
signiﬁcantly longer than expected for their age (Supplementary
Figure S1). Paternal interfamilial correlations for telomere length be-
tween centenarians and their offspring were signiﬁcant (r = 0.401;
p= 0.031), but not maternal ones (Supplementary Figure S2).
3.2. Associations Between Biomarker Domains and Successful Ageing
We regarded capability (Barthel index), cognitive function (MMSE
score), multimorbidity (disease count), and mortality (survival time)
as informative descriptors of functional healthspan or successful ageing.
In contrast to some other indicators of successful/unsuccessful ageing
(e.g., frailty), these are applicable even in the extreme old. In all age
groups, capability, cognition, and mortality were strongly correlated
with each other, while multi-morbidity showed no or spurious correla-
tionswith any of the othermeasures of successful ageing (Supplementary
Table S1).
We found various associations of individual biomarkers with these
descriptors of successful ageing (Supplementary Table S2, Supplementa-
ry Figures S3, S4, and data not shown). However, these biomarkers were
not independent of each other, in fact, they were highly inter-correlated
(Supplementary Table S3). Associations were generally strongest
between markers belonging to the same biological or pathological
process or domain (Supplementary Table S3). This prompted us to cal-
culate domain scores as combined z-scores for multiple markers within
a single domain (inverted and/or log-transformedwhere necessary, see
Methods section) with the aim to describe more comprehensively the
relative impact of whole (patho-)biological domains on the ageing
process.
Analysing all participants together, most of the examined domains
were associated with each other (Supplementary Table S4a). These as-
sociations were partly driven by underlying age and were accordingly
lost in age-speciﬁc analyses (Supplementary Table S4b–d). For instance,
the positive association between inﬂammation and senescence over
the whole age range is reversed in centenarians and lost in semi-
supercentenarians. On the other hand, haematopoiesis, lipid and glucose
metabolism, and liver function generally remained associated with each
other throughout the age groups (Supplementary Table S4b–d), suggest-
ing common underlying processes between these domains.
The associations between biomarker domains and survival in all
independent cohorts were tested by Kaplan-Meier analyses of tertiles
adjusted for age and gender (Fig. 2). Inﬂammationwas the only domain
predicting survival in all age groups, although it did not remain signiﬁ-
cant in the centenarians (100–104 years) after additional adjustments
for education, history of CVD, hypertension, diabetes, hyperlipidaemia,
and low albumin (Supplementary Table S5). Cell senescence (telomere
length) was associated with survival time in the 85–99 years old group
only, but this association was different from expectations as it showed
lowest survival for participants in the middle tertile of telomere length.
Statin use was not different between the tertiles of telomere length
(data not shown). The immunosenescence index could only be calculated
in a subset of the (semi-)supercentenarians anddid not predict survival in
this group (data not shown), although individual immunosenescence
markers were associated with survival (Supplementary Figure S4
and Supplementary Table S2c). Renal function was not associated with
survival in any of the age groups (not shown).
Age group-speciﬁc rank correlations showed a persistent and
preferential association between the inﬂammation score and both
capability and cognition (but not multimorbidity) over all age groups
(Supplementary Table S6). To assess comparatively the impact of
different pathophysiological domains on ageing, we performed forward
stepwise linearmodellingwith each of the outcome indicators as target
variable and age, gender, and all domain indices as predictor variables.
From these models, we calculated the percentage of variation in the
Table 1
Baseline characteristics of the participants.
Family of centenarians Very old Centenarians
Offspring Unrelated family 85–99 years 100–104 years 105–109 years 110+ p
N (male, female) 167 (126, 41) 167 (41, 126) 536 (234, 302) 275 (59, 216) 387 (48, 339) 22 (2, 20) b0.001a
Age at enrollment, median [IQR] 76.5 [71.3, 80.6] 73.2 [68.3, 78.6] 87.4 [86.2, 88.8] 100.7 [100.2, 102.1] 106.8 [105.9, 107.5] 110.7 [110.4, 111.2]
Living conditions, nursing home N (%) 0 (0.0%) 0 (0.0%) 2 (0.4%) 90 (32.7%) 263 (68.0%) 18 (81.8%) b0.001a
Past or current smoking, N (%) 87 (52.1%) 33 (19.8%) 205 (38.2%) 39 (14.2%) 37 (9.6%) 2 (9.1%) b0.001a
Missing data, N (%) 13 (7.8%) 21 (12.6%) 20 (3.7%) 1 (0.4%) 3 (0.8%) 1 (4.5%)
Higher education, N (%) NA NA 195 (36.4%) 58 (21.1%) 40 (10.3%) 2 (9.1%) b0.001a
Missing data, N (%) NA NA 19 (3.5%) 8 (2.9%) 18 (4.7%) 1 (4.5%)
Barthel index, median [IQR] 100 [100, 100] 100 [100, 100] 100 [95, 100] 45 [15, 80] 15 [5, 50] 5 [0, 15]
Missing data, N (%) 18 (10.8%) 28 (16.8%) 7 (1.3%) 3 (1.1%) 6 (1.6%) 1 (4.5%)
MMSE, median [IQR] NA NA 27 [25,29] 14 [8,21] 6 [0, 13] 0 [0, 4]
Missing data, N (%) NA NA 7 (1.3%) 34 (12.3%) 92 (23.8%) 4 (18.2%)
Past medical history, N (%)
Hypertension 66 (42.0%) 65 (41.4%) 336 (62.7%) 98 (35.9%) 147 (38.4%) 8 (36.4%) b0.001a
Diabetes mellitus 21 (13.5%) 22 (14.2%) 100 (18.7%) 19 (6.9%) 22 (5.7%) 2 (9.1%) b0.001a
Hyperlipidaemia 25 (15.0%) 34 (20.4%) 225 (42.0%) 39 (14.2%) 50 (12.9%) 5 (22.7%) b0.001a
Fragility fracture 9 (5.8%) 12 (7.9%) 123 (23.0%) 126 (46.7%) 212 (55.2%) 11 (50.0%) b0.001a
Cancer other than skin 20 (12.9%) 10 (6.6%) 100 (18.9%) 29 (10.8%) 45 (11.7%) 4 (18.2%) 0.474a
Stroke 15 (9.0%) 6 (3.6%) 92 (17.2%) 45 (16.4%) 75 (19.4%) 2 (9.1%) b0.001a
Coronary heart disease 11 (6.6%) 6 (3.6%) 54 (10.1%) 40 (14.5%) 58 (15.0%) 3 (13.6%) b0.001a
Renal disease 6 (3.6%) 9 (5.4%) 57 (10.6%) 22 (8.0%) 27 (7.0%) 0 (0.0%) b0.001a
No of chronic Conditions, Median [IQR] 1 [0,2] 1 [0,2] 2 [1,3] 1 [1,2] 2 [1,2] 2 [1,2]
Missing data, N (%) 13 (7.8%) 15 (9.0%) 9 (1.7%) 8 (2.9%) 5 (1.3%) 0 (0.0%)
Laboratory data, mean ± SD
WBC, /μL 5860 ± 1569 5610 ± 1293 5752 ± 1344 5386 ± 1425 5459 ± 1730 6301 ± 3331 0.029
RBC, ×106/μL 4.44 ± 0.47 4.33 ± 0.42 4.12 ± 0.44 3.62 ± 0.50 3.61 ± 0.55 3.77 ± 0.61 b0.001
Haemoglobin, g/dL 13.8 ± 1.4 13.3 ± 1.3 12.5 ± 1.4 11.3 ± 1.5 11.2 ± 1.6 11.6 ± 1.8 b0.001
Platelets, ×104/μL 21.5 ± 5.5 21.9 ± 5.4 21.7 ± 5.5 18.9 ± 5.8 19.4 ± 6.7 19.3 ± 8.4 b0.001
Missing data, N (%) 2 (1.2%) 1 (0.6%) 4 (0.7%) 10 (3.6%) 10 (2.6%) 0 (0.0%)
Total cholesterol, mg/dL 196 ± 35 212 ± 33 201 ± 33 172 ± 34 165 ± 36 156 ± 34 b0.001
HDL-cholesterol, mg/dL 54 ± 15 58 ± 14 59 ± 15 53 ± 13 45 ± 13 44 ± 13 b0.001
Albumin, g/dL 4.2 ± 0.3 4.2 ± 0.3 4.1 ± 0.3 3.7 ± 0.4 3.4 ± 0.4 3.2 ± 0.4 b0.001
Creatinine, mg/dL 0.78 ± 0.17 0.72 ± 0.48 0.84 ± 0.51 0.89 ± 0.45 0.86 ± 0.43 0.78 ± 0.32 0.002
Missing data, N (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (1.1%) 3 (0.8%) 0 (0.0%)
CMV positive, N (%) 162 (97.6%) 165 (99.4%) 524 (98.1%) 266 (99.6%) 383 (100.0%) 21 (100.0%) 0.133
CMV titer Median [IQR] 18.1 [11.5, 28.1] 21.6 [14.5, 34.2] 18.8 [12.4, 29.1] 27.7 [17.1, 43.9] 29.6 [18.8, 53.0] 25.2 [16.1, 40.4]
Missing data, N (%) 1 (0.6%) 1 (0.6%) 2 (0.4%) 8 (2.9%) 4 (1.0%) 1 (4.5%)
CRP, Median [IQR],mg/dL 0.07 [0.04, 0.14] 0.07 [0.04, 0.16] 0.09 [0.04, 0.19] 0.16 [0.06, 0.44] 0.25 [0.09, 0.80] 0.21 [0.07, 1.15] b0.001
Missing data, N (%) 1 (0.6%) 1 (0.6%) 0 (0.0%) 3 (1.1%) 4 (1.0%) 0 (0.0%)
Interleukin-6, Median [IQR], pg/mL 1.03 [0.65, 1.52] 1.13 [0.78, 1.52] 1.69 [1.29, 2.46] 2.86 [2.26, 4.27] 3.31 [2.41, 5.31] 3.30 [2.40, 6.84] b0.001
TNF-alpha, Median [IQR], pg/mL 1.37 [0.86, 2.06] 2.02 [1.39, 2.47] 2.19 [1.88, 2.79] 3.36 [2.82, 4.24] 4.91 [3.85, 6.49] 4.53 [4.00, 5.38] b0.001
Missing data, N (%) 3 (1.8%) 1 (0.6%) 3 (0.6%) 13 (5.1%) 13 (3.4%) 1 (4.5%)
Lymphocyte surface markers
N (male, female) 17 (15, 2) 17 (2, 15) NA 8 (0, 8) 111 (11, 100) 3 (0, 3)
CD4, % Mean ± SD 44.7 ± 10.1 48.7 ± 12.3 NA 39.3 ± 8.9 38.7 ± 11.7 44.0 ± 18.2
CD8, % Mean ± SD 30.2 ± 10.0 26.4 ± 10.2 NA 30.4 ± 11.0 31.6 ± 11.1 21.6 ± 13.8
CD4/CD8, median [IQR] 1.37 [1.11, 1.91] 1.88 [1.44, 2.32] NA 1.02 [0.88, 2.56] 1.20 [0.91, 1.84] 1.62 [0.81, 10.53]
CD16, % mean ± SD 18.3 ± 9.2 15.3 ± 10.0 NA 33.0 ± 13.6 23.6 ± 14.4 24.4 ± 24.0
CD28, % mean ± SD 47.8 ± 11.6 48.6 ± 15.2 NA 37.8 ± 9.4 36.9 ± 13.6 48.2 ± 19.9
CD56, % mean ± SD 24.2 ± 8.2 18.9 ± 10.4 NA 31.5 ± 12.7 28.8 ± 13.8 28.0 ± 30.8
Telomere length, mean ± SD, bp 3871 ± 621 3773 ± 720 3322 ± 681 3045 ± 761 3387 ± 821 3399 ± 920
Missing data, N (%) 0 (0.0%) 3 (1.8%) 4 (0.7%) 0 (0.0%) 6 (1.6%) 0 (0.0%)
a p-value is for a two-sided Cochran–Armitage Trend Test.
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(Figs. 3a–c). Inmodels combining data fromall age groups, unsurprisingly
age was the most important predictor of capability and cognition. Inter-
estingly, inﬂammation was the next important predictor of cognition
and was only just surpassed in impact for capability by renal function.
Combining all age groups, inﬂammation was a more relevant predictor
than gender (Figs. 3a,b). Although renal function predicted capability
and cognition in the centenarians (Figs. 3 a,b), the associations were
negative (suppl. Tab. S6b, c), probably reﬂecting the fact that serum
creatinine is highly dependent on muscle mass, which is low in the
extreme old.
Multi-morbidity alone showed a different pattern. Predictive power
of any target variable including age was low, with lipid and glucose
metabolism as the prime factor. This remained consistently so when
analyses were performed in the age groups separately (Fig. 3c).
Age group-speciﬁc analyses showed that despite considerable
intra-group age differences, age itself was only exceptionally (i.e. incentenarians) a signiﬁcant predictor of capability, cognition, or
multimorbidity. Importantly, inﬂammation was the only domain
that contributed signiﬁcantly to the variance of capability and cognition
outcomes in all age groups, and its relevance increased with age to
become the largest predictor in (semi-)supercentenarians (Figs. 3a–c).
3.3. Lower Inﬂammation Index in Centenarian Offspring
For traditional reasons, thereweremoremales in the offspring group
and, associated with male gender, a slightly increased age at enrolment
and a higher frequency of smokers (Table 1). The only signiﬁcant differ-
ence in individual biomarkers between offspring and their spouseswas a
decrease in total cholesterol (Table 1). Although centenarian offspring
maintained their telomeres better with age than unrelated participants
(Fig. 1) so that their telomere lengths were signiﬁcantly above the
age-dependent mean for unrelated 50 to 99 year olds (Supplementary
Figure S1), differences in the senescence indices between centenarian
Fig. 1. Telomere length in study participants up to 115 years of age. Leukocyte telomere
length vs age is shown for males (blue or cyan) and females (green or red). Centenarians,
(semi-)supercentenarians, and centenarian offspring are shown in blue (males) or red
(females), respectively. Unrelated participants younger than 100 years are indicated in
cyan (males) or green (females). Regression lines belonging to these groups are indicated
by the same colour.
1554 Y. Arai et al. / EBioMedicine 2 (2015) 1549–1558offspring and their spouses did not reach statistical signiﬁcance
(Table 2). This is probably because of the higher abundance of males
(with shorter telomeres) in the offspring group. However, a comparison
of domain scores revealed that centenarian offspring showed the lowest
inﬂammation index of all groups including their spouses, with themag-
nitude of the differences increasing with progressing age (Table 2) in
line with previous data from a Dutch cohort (Derhovanessian et al.,
2010). Centenarian offspring also displayed lower values for the lipid
and glucose index than their spouses, but were more similar to the
very old and extreme old groups than their spouses for this score
(Table 2). There were no signiﬁcant differences between offspring and
spouses in the haematopoiesis, liver and renal function domains.
4. Discussion
We aimed to identify biological domains that predict successful
ageing at extreme old age and to see whether improved performance
in these domains would already be recognizable in centenarian
offspring. Thus, we comparatively analysed the association of multiple
domains, spanning a range of physiological and pathological processes
that may contribute to ageing, with multiple indicators of successful
ageing in an unprecedentedly large cohort of centenarians and
(semi-)supercentenarians, their offspring and spouses, and an unrelated
cohort of the very old. This allowed us to identify low-level inﬂammation
as, after age itself, the most important correlate of not only survival, but
also capability and cognition. Over all groups combined and, especially,
in the (semi-)supercentenarians, the impact of inﬂammation on these
main indicators of successful ageing is stronger than that of gender,
haematopoiesis/anaemia, liver or kidney function, lipid and glucose
metabolism, or immune cell senescence. Renal function appeared as a
similarly strong predictor of capability, but this was most probably due
to its association with low muscle mass. Furthermore, only the inﬂam-
mation index is consistently lower in centenarian offspring as compared
to their spouses and older cohorts (even despite an inverted gender
ratio). These results conﬁrm and extend data from younger and/or
smaller cohorts (Jenny et al., 2012; Akbaraly et al., 2013; Schnabel
et al., 2013; Varadhan et al., 2014). They emphasize the apparent
paradox, recognized earlier (Salvioli et al., 2013), that on one hand sys-
temic inﬂammation is associated with accelerated ageing and enhanced
mortality risk, while on the other hand centenarians, who have escaped
those risks for longer and age slower than the general population, showhigh levels of systemic inﬂammation markers. One approach to explain
this was the suggestion that not the total, systemic amount of pro-
inﬂammatory mediators but their tissue- and cell-speciﬁc origin and
place of action might determine whether they are dangerous for health
and longevity or actually good for physiological responses. As another
not mutually exclusive possibility, it was suggested that high levels of
anti-inﬂammatory molecules in long-living people may counteract
inﬂamm-ageing, both suggestions implying that high systemic levels of
pro-inﬂammatory molecules would not confer increased risks in cente-
narians (Salvioli et al., 2013). Our data suggest another interpretation:
Seeing low levels of systemic inﬂammation in centenarian offspring
indicated that the rise of inﬂammatory mediators in centenarians may
be a relatively late, ‘catch-up’ event. Thus, future centenarians may be
risk-protected over most of their lifespan by low levels of systemic
inﬂammation, but when these levels rise towards the end of their
lifespan they predict centenarian mortality, disability and cognitive
decline at least as strongly as in the general population.
This interpretation is consistent with results from animal studies. In
mice, as in humans, enhanced systemic inﬂammation is associated with
accelerated ageing and increased mortality risk (Osorio et al., 2012;
Kawahara et al., 2009; Tilstra et al., 2012; Caballero et al., 2009). Impor-
tantly, systemic activation of the major pro-inﬂammatory transcription
factor NF-κB in the absence of any other genetic or environmental factor
is sufﬁcient to accelerate ageing in mice, suggesting that chronic
enhancement of pro-inﬂammatory mediators is not just a bystander
but a driver of ageing (Jurk et al., 2014).
Together, our results suggest suppression of chronic inﬂammation as
a major determinant of successful longevity, which is relevant over a
very wide age range up to extreme old age. Further human studies in
independent cohorts of the extreme old will be necessary to address
the generalisability of these results.
Anti-inﬂammatory interventions have proven power to rescue pre-
mature ageing in mice (Jurk et al., 2014; Tilstra et al., 2012; Strong
et al., 2008). However, serious side effects of available potent anti-
inﬂammatories presently preclude their long-term use in humans
(Jaturapatporn et al., 2012; Pellicano, 2014; Rainsford, 2007; Strand,
2007). Potentially, more pleiotropic drugs like melatonin that include
anti-inﬂammatory effects in a wide action spectrum could offer safer
alternatives (Caballero et al., 2009; Hardeland, 2013). Our results
suggest that the development of more sophisticated and safer anti-
inﬂammatory strategies could be an essential step towards the preven-
tion of human premature ageing.
In our centenarian and (semi-)supercentenarian cohorts, multi-
morbidity was not associated with other outcome indicators of the
ageing process (Barthel index, MMSE or survival time) and was
not predicted by markers of inﬂammation. Signiﬁcant associations
between inﬂammation markers and multimorbidity in the very old
have been found in many (Stepanova et al., 2015) but not all (Martin-
Ruiz et al., 2011) previous studies. The operational deﬁnition of
multimorbidity is a potential problem; previous studies used disease
counts including any number from 9 to 35 different items either self-
rated, clinician-rated or record-extracted, or a number ofmore complex
scores or scales (Huntley et al., 2012). Due to the problematic nature of
clinical diagnoses at extreme old age, we restricted ourselves to a list of
only 8 clinically veriﬁed diagnoses, omitting for instance arthritis,
osteoporosis, pulmonary disease, respiratory disease, thyroid disease,
and dementia but including in contrast to many other studies fragility
fractures. To test the sensitivity of our conclusions to the speciﬁc opera-
tional deﬁnition of multimorbidity, we calculated alternative disease
counts either including diagnosed dementia (given that cognitive status
as measured by MMSE is dependent on inﬂammation score) or exclud-
ing frailty fracture (which is the most frequent condition in the over
100's and might be regarded as an accident rather than a chronic
disease). However, associations of the so modiﬁed disease counts with
other ageing outcome indicators or with the inﬂammation score
still remained insigniﬁcant in all age groups tested. We conclude that
Fig. 2.Kaplan–Meier survival curves for tertiles of biomarker domains and telomere length in the very old, centenarian, and (semi-)supercentenarian group. For each age group, the domainswere independently organized into tertiles and assessed as
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extreme old, it still indicates that multimorbidity in our populations is
not governed by inﬂammation anddoes not co-varywith either survivaltime, capability or cognitive function. Whether this is because of the
extreme age or some other property of our study population can only
be assessed by comparison to independent cohorts.
Telomere length in offspring was related to that of their centenarian
fathers, but not to that of centenarianmothers. Previous studies demon-
strated signiﬁcant cohort heterogeneity in terms of mother-offspring vs
father-offspring telomere length correlations (Eisenberg, 2014),
however, it is now well established that paternal but not maternal age
at conception predicts offspring telomere length (Broer et al., 2013). It
is possible that this paternal age effect explains the father–offspring
association seen here.
Cross-sectionally, our data show superior maintenance of
telomere length in centenarian offspring, centenarians and
(semi-)supercentenarians. They conﬁrm the ﬁnding of improved
telomere length maintenance in Ashkenazy centenarians (Atzmon
et al., 2010) in a genetically independent, large cohort. They
raise doubt about the validity of previous claims suggesting equal
telomere shortening in centenarians (Kimura et al., 2007) or a
fast drop of telomere length between centenarians and semi-
supercentenarians (Tedone et al., 2014) that were derived from
very low numbers of participants. Together, our data suggest that
long telomeres might be a prerequisite for exceptional lifespan in
humans. They also suggest that centenarian offspring is able to coun-
teract telomere shortening that occurs in the general population and
this might contribute to their higher probability of longevity. It is
possible that people with exceptional longevity, who also maintain
very low risks of CVD, diabetes, and auto-immune diseases, escape
from telomere-driven pathologies by maintaining relatively long
telomeres.
Given that inﬂammation and telomere-dependent cell senescence
can drive each other thus causing accelerated ageing (Jurk et al., 2014;
Tchkonia et al., 2013),wewere surprised to ﬁnd evidence for inﬂamma-
tion as driver of ageing up to (semi-)supercentenarians, while telomere
length/cell senescence was no longer predictive for successful ageing
once longevity had been achieved. In a previous study comprising
only 38 participants, longer telomeres were associated with better
health and independence in centenarians (Terry et al., 2008). However,
other studies had shown before that telomere length loses its predictive
power as a biomarker of mortality and morbidity risk at ages above 75
years (Cawthon et al., 2003; Martin-Ruiz et al., 2005). Moreover,
therewere a number of limitations to our assessment of cell senescence.
Firstly, there are technical limitations with the reproducibility of
telomere length measurements (Martin-Ruiz and von Zglinicki, 2014;
Martin-Ruiz et al., 2014). In addition, telomere length is limited as a
biomarker of senescence because telomere dysfunction can induce
senescence without concomitant telomere shortening (Jurk et al.,
2014; Hewitt et al., 2012). Due to biobanking limitations, further senes-
cence markers like p16 could not be included in the study. Second,
latent CMV infection is associated with both immunosenescence and
chronic inﬂammation (Sansoni et al., 2014). However, using plasma
CMV titers as part of the senescence score did not result in a stronger
predictive power of cell senescence for successful ageing (data not
shown). We also used T cell surface markers, speciﬁcally CD4 and
CD28, as an additional indicator of immunosenescence. This approach
was unprecedentedly well powered in the semi-supercentenarian
group, but we were not able to analyse good numbers of participants
from the other study groups. Low proportions of CD28+ naive T cells,
indicating higher fractions of memory/senescent T cells in the peripher-
al blood, predicted decreased survival in the (semi-)supercentenarians.Fig. 3. Predictors of capability (a), cognition (b), andmulti-morbidity (c). Forward stepwise
model selection was performed with age, gender, and all domain scores as predictors.
Models were run separately for all unrelated participants and for each of the indicated
age groups. Bars indicate the percentage of target variance explained by each predictor.
All signiﬁcant predictors (p b 0.05) in each group are shown. The total variance explained
by each model is given (as %) on top.
Table 2
Differences in group domain scores to centenarian offspring.
Offspring against Mean difference Std. error Signiﬁcance 95% conﬁdence interval
Lower bound Upper bound
Haematopoiesis Unrelated Family 0.573 0.229 0.092 −0.054 1.199
Very old (85–99 years) 1.238⁎ 0.186 0.000 0.730 1.745
Centenarians (100–104 years) 3.146⁎ 0.207 0.000 2.581 3.711
(Semi)-Supercentenarians (105 years+) 3.074⁎ 0.193 0.000 2.547 3.601
Inﬂammation Unrelated Family −0.795⁎ 0.235 0.006 −1.436 −0.154
Very old (85–99 years) −1.805⁎ 0.190 0.000 −2.324 −1.285
Centenarians (100–104 years) −4.077⁎ 0.213 0.000 −4.657 −3.496
(Semi)-Supercentenarians (105 years+) −5.278⁎ 0.198 0.000 −5.818 −4.737
Lipid & Glucose Unrelated Family −0.950⁎ 0.230 0.000 −1.578 −0.322
Very old (85–99 years) −0.384 0.187 0.241 −0.895 0.127
Centenarians (100–104 years) 1.311⁎ 0.208 0.000 0.742 1.879
(Semi)-Supercentenarians (105 years+) 1.732⁎ 0.194 0.000 1.202 2.262
Liver function Unrelated family 0.266 0.264 0.851 −0.454 0.987
Very old (85–99 years) 0.665⁎ 0.214 0.016 0.081 1.249
Centenarians (100–104 years) 2.186⁎ 0.237 0.000 1.539 2.833
(Semi)-Supercentenarians (105 years+) 1.932⁎ 0.222 0.000 1.327 2.538
Renal function Unrelated family −0.049 0.105 0.991 −0.336 0.239
Very old (85–99 years) 0.426⁎ 0.085 0.000 0.193 0.659
Centenarians (100–104 years) 0.736⁎ 0.095 0.000 0.478 0.994
(Semi)-supercentenarians (105 years+) 0.666⁎ 0.089 0.000 0.425 0.908
Senescence Unrelated family −0.127 0.104 0.738 −0.412 0.157
Very old (85–99 years) −0.709⁎ 0.084 0.000 −0.938 −0.480
Centenarians (100–104 years) −1.066⁎ 0.093 0.000 −1.320 −0.813
(Semi)-supercentenarians (105 years+) −0.624⁎ 0.087 0.000 −0.862 −0.386
⁎ p b 0.05.
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cells in the whole study cohort (Supplementary Table 3), but not in
(semi-)supercentenarians (r =−0.110; p = 0.193). This might indi-
cate that humans with exceptional longevity are less susceptible to
CMV-associated immunosenescence in accordance with earlier studies
(Derhovanessian et al., 2010).
There are additional limitations to our study, the most important
being that not all domains could be assessed with sufﬁcient participant
numbers in all age groups. Moreover, numbers of individual parameters
spanning a domain are variable, which might make some domain
descriptions less powerful than others. Creatinine-based estimation of
glomerular ﬁltration rate (eGFR) by using any formula has not been
properly validated in the very old and centenarians due to its strong
dependency on muscle mass (Stevens et al., 2006), which limits the
predictive power of the kidney function domain. In addition, we are
aware of the risk to lose speciﬁc information by analysing process
domains rather than individual candidate biomarkers. However, we be-
lieve that random variation, both technical and biological, is the most
important source of differences between biomarker patterns describing
the same pathophysiological process. Creating biomarker domains by
non-weighted averaging of z scores reduced this random variation.
Despite these limitations, our study showed that over a very wide
age range from 45 to 115 years, including unprecedentedly large num-
bers of the extremely old, inﬂammation is an important driver of ageing
thatmight be amenable to future pharmacological intervention. Accord-
ingly, designing novel, safe anti-inﬂammatory or immune-modulating
medication has major potential to improve healthy lifespan.
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